BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 9, 2013
View Archived Issues
Uncovering the mechanism of action of a potent, small-molecule inhibitor of human prostate cancer
Read More
mRNA-mediated inhibition of transcription improves cardiovascular disease-related etiologies
Read More
PurGenesis' phase IIa trial of PUR-0110 in ulcerative colitis meets primary endpoint
Read More
A small-molecule design strategy for increasing the potency of RNA-targeting compounds
Read More
Telormedix receives funding for new psoriasis treatment
Read More
Lupin acquires exclusive U.S. rights to Alinia from Romark
Read More
Evidence for the success of a DNA vaccine against AD in non-human primates
Read More
PTC Therapeutics selects candidate for spinal muscular atrophy collaboration
Read More
Quantification of serum glucose levels demonstrated with NMR assay
Read More
First patient dosed in phase IIa part of ATU-027 combination study
Read More
FDA grants orphan drug status to E-7777 for cutaneous T-cell lymphoma
Read More
Cleveland BioLabs and Incuron begin phase I trial of CBL-0137 in the U.S.
Read More
Keryx Biopharmaceuticals submits NDA for Zerenex
Read More
Ajinomoto presents new TRPA1 antagonists
Read More
Duke University patents novel vaccines for the treatment of cancer
Read More
NuMe Health changes name to MicroBiome Therapeutics
Read More
Vaccines for tularemia disclosed by Albany Medical Center
Read More
European license for Velcade extended
Read More
New agents for cancer patented by Shanghai Allist Pharmaceuticals
Read More
Lu-AE-58054 is a safe and effective add-on therapy to acetylcholinesterase inhibitors
Read More
Threshold commences phase II study of hypoxia-targeted drug in advanced melanoma
Read More
GSK to discontinue manufacture and sale of Bexxar anticancer regimen
Read More
Teva obtains European approval for Lonquex to help manage neutropenia during chemotherapy
Read More
Benitec and University of New South Wales execute license agreement for Tribetarna program
Read More
Pomalidomide approved by European Commission for multiple myeloma
Read More